Blog Chronic Condition Clinic Individual 
GeriPal
MAY 19, 2022
It depends on the clinical situation. As I’ve been blogging about this for a couple months now, I’m really trying to find anyone who loves these things. But we still, regardless of how you do this calculation have to temper it with clinical judgment. Drew: I’ve published a draft version of it on the blog.
FDA Law Blog
JUNE 27, 2024
to promote therapeutic appropriateness by identifying: (a) Over-utilization or under-utilization; (b) Therapeutic duplication; (c) Drug-disease contraindications; (d) Drug-drug interactions; (e) Incorrect drug dosage or duration of drug treatment; (f) Drug-allergy interactions; [and] (g) Clinical abuse/misuse.” By Larry K. a), 1306.06.
FDA Law Blog
SEPTEMBER 13, 2021
Currently, individual Medicare Part D plan sponsors negotiate rebates but the government is explicitly prohibited from interfering in those negotiations. One proposal is a cap on out-of-pocket costs, primarily to help beneficiaries with expensive chronic conditions that can face large, even catastrophic, out-of-pocket spending every year.
Expert insights. Personalized for you.
139 
Let's personalize your content